GI
SPRO icon

Gradient Investments’s Spero Therapeutics SPRO Stock Holding History

Gradient Investments’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-203
Closed -$2K – 1186
2020
Q1 		$2K Buy
203
+26
+15% +$229 ﹤0.01% 937
2019
Q4 		$2K Buy
+177
New +$1.91K ﹤0.01% 961

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Gradient Investments's SPRO Position: Q2 2020 in Review

Gradient Investments sold out of Spero Therapeutics (SPRO) in Q2 2020, closing a stake of 203 shares — an estimated $2K sold.

Gradient Investments first reported a position in SPRO in Q4 2019 and held it in 2 quarters. The position peaked at $2K in Q1 2020. 80 funds tracked by Wall St. Rank hold SPRO as of Q2 2020.

  • Gradient Investments reported no remaining Spero Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Gradient Investments sold 203 Spero Therapeutics shares in Q2 2020, an estimated $2K.
  • Gradient Investments first reported a position in Spero Therapeutics in Q4 2019 and held it in 2 quarters.
  • Gradient Investments's Spero Therapeutics position peaked at $2K in Q1 2020.
  • 80 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2020.

Based on Gradient Investments's 13F filing for Q2 2020, filed 10 Jul 2020.